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Background/Aims: The optimal timing for initiation of anti-tumor necrosis fac-
tor (TNF) therapy in Crohn’s disease (CD) is still debated. Little is known about 
the clinical outcomes of early versus late administration of anti-TNF agents, es-
pecially in Asian CD patients. We aimed to evaluate the impact of early anti-TNF 
therapy on clinical outcomes in Korean CD patients. 
Methods: Using the Korean National Health Insurance Claims database, we col-
lected data on patients diagnosed with CD who received anti-TNF therapy for 
more than 6 months between 2010 and 2016. Early initiation of anti-TNF therapy 
was defined as those starting infliximab or adalimumab therapy within 1 year of 
diagnosis. The following outcomes were assessed using a Cox proportional haz-
ard model: abdominal surgery, CD-related emergency room (ER) visit, CD-related 
hospitalization, and new corticosteroid use. 
Results: Among 1,207 patients, 609 were early initiators of anti-TNF. Late an-
ti-TNF initiation (> 1 year after diagnosis) was associated with increased risk of 
surgery (adjusted hazard ratio [aHR], 1.64; 95% confidence interval [CI], 1.05 to 2.55) 
and tended to be associated with increased risk of ER visit (aHR, 1.38; 95% CI, 0.99 
to 1.94). However, there were no significant differences in the risk of hospitaliza-
tion and corticosteroid use between early and late initiators.
Conclusions: Early anti-TNF therapy among Korean CD patients within 1 year 
of diagnosis was associated with better clinical outcomes than late therapy, such 
as lower surgery and ER visit rates. Our results suggest that aggressive medical 
intervention in the early stages of CD may potentially change the course of this 
disease.
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INTRODUCTION
Crohn’s disease (CD) is a relapsing and remitting in-
flammatory bowel disease (IBD) that leads to bowel 
damage and impaired gut function [1]. It is a chronic and 
incurable disease that requires life-long medical treat-
ment. The medical management of CD has dramatically 
changed over the past few decades with the advent of 
biological agents targeting tumor necrosis factor-alpha 
(TNF-α), including infliximab and adalimumab [2]. Mu-
cosal healing induced by these agents appears to bring 
about changes in the natural history of CD [3]. The AC-
CENT II trial (A Crohn's Disease Clinical Trial Evalu-
ating Infliximab in a New Long-Term Treatment Reg-
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imen in Patients with Fistulizing Crohn's Disease) and
CHARM (Crohn’s Trial of the Fully Human Antibody 
Adalimumab for Remission Maintenance) studies re-
vealed that infliximab and adalimumab maintenance 
therapy reduced hospitalization and surgeries in pa-
tients with CD [4,5]. 
Although anti-TNF therapy is associated with better 
clinical outcomes, the use of anti-TNF agents is often 
postponed until after failure of other treatment mo-
dalities. A delay in effective medical therapy can lead 
to chronic and uncontrolled inflammation, resulting 
in irreversible complications such as stenosis and fis-
tula. Indeed, previous studies have shown that use of 
immunomodulators (IMs) and/or biologics early in the 
course of the disease, known as top-down or accelerated 
step-up strategies, is superior to conventional step-up 
therapy in patients with CD [3,6,7]. In addition, several 
recent studies have compared early and late initiation of 
anti-TNF therapy in CD and have demonstrated better 
clinical outcomes in early initiators than in late initia-
tors [8-11]. However, most previous studies on this topic 
have been conducted in Western countries. Relatively 
little is known about the effectiveness of early use of an-
ti-TNF agents in Asian patients with CD, and it is ques-
tionable whether the results of studies involving West-
ern patients can be extrapolated to Asian patients. The 
optimal timing of anti-TNF therapy initiation remains 
a challenging issue, especially in Asian patients with CD.
Therefore, we performed a nationwide population- 
based study to assess the effect of early initiation of an-
ti-TNF agents on clinical outcomes in Korean patients 
with CD, by using a health claims administrative data-
base. We compared clinical outcomes (including abdom-
inal surgery, CD-related emergency room (ER) visits, hos-
pitalization rates, and new corticosteroid use) between 
early versus late initiators of infliximab or adalimumab 
during maintenance therapy in a real-life clinical setting. 
METHODS
Study design and data source 
We conducted a retrospective population-based study 
using a database provided by the National Health In-
surance Service (NHIS) in South Korea between 2008 
and 2016. The Korean NHIS is a mandatory nationwide 
insurance system that covers the entire population of 
South Korea (approximately 51 million people). All in-
formation regarding health care utilization gathered 
by the NHIS is registered in a comprehensive database, 
which is operated by the Health Insurance Review and 
Assessment Service (HIRA). Medical institutions elec-
tronically submit all health care use information to en-
sure reimbursement, and this information is integrat-
ed into the HIRA database. The HIRA database covers 
a wide range of information on all patients, including 
demographic characteristics, ambulatory care history, 
prescriptions, procedures, and diagnostic codes defined 
by the International Classification of Diseases 10th Re-
vision (ICD-10) [12-14].
All identifiable personal information in the medical 
records was de-identified to comply with the Health In-
surance Portability and Accountability Act privacy rule. 
In addition, as the information in the HIRA database is 
encrypted, the database does not contain personal iden-
tifiers. This study protocol was approved by the Sever-
ance Hospital Institutional Review Board (IRB), Yonsei 
University College of Medicine (IRB No. 4-2017-0927). 
Written informed consent by the patients was waived 
due to a retrospective nature of our study.
Patient identification and definitions 
To ensure that only patients accurately diagnosed as 
having CD were analyzed, we only included patients with 
both appropriate diagnostic codes as well as CD-related 
drug prescriptions [12-14]. ICD-10 codes K50.0–50.9 were 
used to denote CD. CD-related drug prescriptions were 
defined as prescriptions of 5-aminosalicylic acid (5-ASA) 
for 1 month or more, IMs (azathioprine or 6-mercapto-
purine) at least once, and/or biologics at least once [12-
14]. To rule out the use of drugs for other autoimmune 
diseases, only prescriptions received from gastroenter-
ology clinics were considered. 
The date of CD registration in the HIRA database was 
regarded as the date of diagnosis. Considering that pre-
vious prevalent cases could confound the incidence rate, 
we used a washout period of 2 years; thus, we were able 
to analyze patients who were diagnosed with CD and 
received anti-TNF therapy between January 1, 2010 and 
December 31, 2016. 
Because the effects of anti-TNF therapy on long-term 
outcomes could not be assessed with short-term treat-
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ment, patients were excluded from the analysis if they 
underwent anti-TNF therapy for less than 6 months. Pa-
tients with a history of abdominal surgery before starting 
anti-TNF therapy were also excluded from the analysis, 
as the efficacy of anti-TNF therapy can differ between pa-
tients with and those without a history of surgery. 
Patients were stratified by the time of first dose of in-
duction anti-TNF agent after the diagnosis. Early initia-
tion of anti-TNF therapy was defined as starting inflix-
imab or adalimumab therapy within 1 year of diagnosis, 
whereas late initiation of anti-TNF therapy was defined 
as starting infliximab or adalimumab therapy > 1 year 
after diagnosis. 
Because of the poor performance of claims codes for 
perianal diseases, we considered the surgical history of 
perianal diseases. Surgical history of perianal disease 
was defined as the presence of surgical procedure codes 
for anal fissure (Q2950), anal fistula (Q2974, Q2975, Q2976 
Q2977, Q2978, and Q2979), or periproctal abscess (Q2881, 
Q2882, and Q2883) before starting biological therapy.
Outcomes 
The primary objective of this study was to determine if 
early initiation of anti-TNF therapy affected the need 
for (1) abdominal surgery, (2) CD-related ER visits, (3) 
CD-related hospitalization, or (4) new corticosteroid use 
during anti-TNF maintenance therapy. Abdominal sur-
gery was identified by using the procedural code for ma-
jor surgery and defined by the presence of surgical pro-
cedure codes with bowel resection as follows: colectomy 
(Q1261, Q1262, Q2672, Q2673, Q2679, QA672, and QA673), 
total coloprotectomy (QA925), right or left hemicolecto-
my (Q2671 and QA671), resection of the small intestine 
(Q2650 and Q2651), and resection of intestine (Q2691, 
Q2761, and Q2771). Appendectomy (Q2861, Q2862, and 
Q2863) was not included in the definition of abdominal 
surgery. ER visits were defined as patient visits to the ER 
with CD as the primary diagnosis. Hospitalizations were 
defined as cases where the patient was admitted to the 
department of gastroenterology for 3 days or more. New 
corticosteroid use was defined as moderate- to high-
dose corticosteroid use (≥ 30 mg prednisolone, ≥ 50 mg 
methylprednisolone, or ≥ 200 mg hydrocortisone) 2 
months after the first prescription of anti-TNF therapy. 
Statistical analysis
Incidence rates for surgery, ER visits, hospitalizations, 
and the need for corticosteroids were calculated per 
100 person-years, with 95% confidence intervals (CIs) 
using a Poisson distribution. The crude risk of out-
comes in early versus late initiators was compared by 
the Kaplan-Meier method and log-rank tests. We used 
Cox proportional hazards models to adjust for potential 
confounding variables. Baseline factors including sex, 
age, type of first anti-TNF agent (infliximab or adali-
mumab), region, hospital scale, and surgical history of 
perianal disease were adjusted as time-fixed covariates. 
The period of use of anti-TNF agents and the use of IMs 
were adjusted as time-dependent covariates. The results 
are presented as hazard ratios (HRs) with corresponding 
95% CIs. All analyses were performed using the SAS En-
terprise Guide (SAS Institute Inc., Cary, NC, USA), and 
p values < 0.05 were considered statistically significant.
RESULTS
Baseline patient demographics
We identified 8,974 patients diagnosed with CD be-
tween 2010 and 2016, 1,838 of whom started their first 
anti-TNF agents during the study period. Of these 1,838 
patients, 471 were excluded because they received an-
ti-TNF therapy for a period of less than 6 months, and 
160 were excluded because they underwent abdominal 
51 Million people in Korean National Health Insurance claims database
8,974 New Crohn’s disease (CD) patients identified between 2010-2016
1,838 CD patients used anti-TNFagents
1,207 CD Patients (609 early initiators and 598 late initiators)
Exclusion
· 471 Patients who received anti-TNF therapy for less than 6 months
· 160 Patients who had abdominal surgery before the start of 
    anti-TNF therapy
Figure 1. Flow diagram for patient selection. TNF, tumor 
necrosis factor.
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surgery before the start of anti-TNF therapy. Ultimate-
ly, 1,207 patients were included in the study, of whom 
609 were early initiators of anti-TNF (≤ 1 year) and 598 
were late initiators of anti-TNF (> 1 year) therapy (Fig. 
1). The median period from CD diagnosis to anti-TNF 
initiation in all 1,207 patients was 1.0 years (interquar-
tile range [IQR], 0.4 to 2.2). Among the 609 early initia-
tors, 410 (67.3%) started with infliximab and 199 (32.7%) 
started with adalimumab. Among the 598 late initiators, 
305 (51.0%) and 293 (49.0%) started with infliximab and 
adalimumab, respectively. 
Table 1 describes the baseline characteristics of early 
and late initiators of anti-TNF therapy. Sex and age at 
diagnosis of CD were similar between the two groups. 
The age at the time of first anti-TNF use was lower in 
early initiators than in late initiators, and the mean pe-
riod of anti-TNF use was longer in early initiators than 
in late initiators. The rates of 5-ASAs and steroid use at 
Figure 2. Kaplan-Meier survival analysis for clinical outcomes of anti-tumor necrosis factor therapy. Cumulative probabilities 
of (A) abdominal surgery, (B) emergency room visit, (C) hospitalization, and (D) new corticosteroid use. CD, Crohn’s disease.
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first anti-TNF use were higher in early initiators than in 
late initiators, while the rate of concomitant IM use was 
not different between the two groups. The proportion of 
patients who first started anti-TNF therapy in the Seoul 
region and at tertiary hospitals was lower among early 
initiators than among late initiators. Surgical history of 
perianal disease before anti-TNF use was higher in late 
initiators than in early initiators (6.9% vs. 3.6%, p = 0.016).
Comparison of clinical outcomes between early and 
late initiators of anti-TNF
Late initiators of anti-TNF showed significantly high-
er cumulative probabilities of abdominal surgery (p = 
0.016) (Fig. 2A) and CD-related ER visit (p = 0.036) (Fig. 
2B) than early initiators of anti-TNF. However, there 
were no significant differences in the cumulative prob-
abilities of CD-related hospitalization (p = 0.349) (Fig. 
2C) and corticosteroid use (p = 0.515) (Fig. 2D) between 
early and late initiators. At 1, 3, and 5 years after starting 
the first anti-TNF agent, cumulative rates of abdominal 
surgery were 3.1%, 6.5%, and 9.2%, respectively, among 
early initiators, and 4.4%, 9.7%, and 17.8%, respectively, 
among late initiators. 
Median time to surgery, ER visit, hospitalization, and 
corticosteroid use after anti-TNF initiation was similar 
between early and late initiators (Table 2). 
Table 1. Baseline characteristics of study population
Characteristic
Early initiators of anti-TNF
(n = 609)
Late initiators of anti-TNF
(n = 598)
p value
Male sex 422 (69.3) 431 (72.1) 0.319
Age at diagnosis of CD, yr 24.8 ± 11.3 24.9 ± 10.7 0.925
< 30 473 (77.7) 451 (75.4) 0.393
≥ 30 136 (22.3) 147 (24.6)
Age at the start of anti-TNF 25.2 ± 11.3 27.4 ± 10.7 < 0.001
The period from CD diagnosis to first anti-TNF use, yr 0.4 ± 0.3 2.5 ± 1.2 < 0.001
Anti-TNF use period, yr 2.5 ± 1.6 2.2 ± 1.3 < 0.001
First anti-TNF agent
Infliximab 410 (67.3) 305 (51.0) < 0.001
Adalimumab 199 (32.7) 293 (49.0)
Medication use at first anti-TNF use
5-ASAs 379 (62.2) 334 (55.9) 0.028
Steroids 173 (28.4) 107 (17.9) < 0.001
Immunomodulators 344 (56.5) 323 (54.0) 0.420
Concomitant immunomodulators (+/– 30 days) 462 (75.9) 447 (74.8) 0.703
Previous immunomodulators exposure 518 (85.1) 549 (91.8) < 0.001
Region at first anti-TNF use
Seoul 251 (41.2) 310 (51.8) < 0.001
Outside Seoul 358 (58.8) 288 (48.2)
Hospital scale at first anti-TNF use
Tertiary hospitals 420 (69.0) 458 (76.6) 0.004
General hospitals/community hospitals/clinics 189 (31.0) 140 (23.4)
Surgical history of perianal disease before anti-TNF usea 22 (3.6) 41 (6.9) 0.016
Values are presented as number (%) or mean ± SD.
TNF, tumor necrosis factor; CD, Crohn’s disease; 5-ASA, 5-aminosalicylic acid. 
a Surgical history of perianal disease was defined as the presence of surgical procedure codes for anal fissure (Q2950), anal fis-
tula (Q2974, Q2975, Q2976 Q2977, Q2978, and Q2979), or periproctal abscess (Q2881, Q2882, and Q2883) before starting biolog-
ical therapy.
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Cox proportional hazard regression analysis for 
factors associated with clinical outcomes
The HRs in univariate and multivariable Cox propor-
tional hazards models are summarized in Table 3. Uni-
variate analysis showed that late initiation of anti-TNF 
therapy was associated with increased risks of surgery 
(HR, 1.68; 95% CI, 1.10 to 2.59) and ER visit (HR, 1.42; 95% 
CI, 1.02 to 1.96). Even after adjustment for confound-
ing variables, late initiation of anti-TNF therapy was 
independently associated with a higher risk of surgery 
(adjusted hazard ratio [aHR], 1.64; 95% CI, 1.05 to 2.55) 
and tended to be associated with a higher risk of ER vis-
it, although this result was not statistically significant 
(aHR, 1.38; 95% CI, 0.99 to 1.94). However, there were no 
significant differences in the risk of hospitalization and 
corticosteroid use between early and late initiators. 
In multivariable Cox regression analysis, several oth-
er factors were also identified as being associated with 
clinical outcomes. Age at the start of anti-TNF therapy 
was associated with increased risk of surgery (aHR, 1.02; 
95% CI, 1.01 to 1.04), hospitalization (aHR, 1.01; 95% CI, 
1.01 to 1.02), and corticosteroid use (aHR, 1.02; 95% CI, 
1.01 to 1.03). The anti-TNF use period (/years; aHR, 0.81; 
95% CI, 0.69 to 0.95) and initiation of anti-TNF in the 
Seoul region (aHR, 0.73; 95% CI, 0.58 to 0.93) were asso-
ciated with a reduced risk of hospitalization. The use of 
adalimumab initiators was associated with a higher risk 
of ER visits than that of infliximab initiators (aHR, 1.85; 
95% CI, 1.32 to 2.59). 
Because previous studies have proposed a cut-off time 
of 2 years for early CD treatment [8-11], we conducted fur-
ther analysis to assess the effect of initiation of anti-TNF 
therapy within 2 years after diagnosis. Of 1,207 patients, 
873 started anti-TNF therapy within 2 years of diagnosis, 
and 334 started anti-TNF therapy > 2 years after diagnosis. 
In multivariable Cox regression analysis, late initiation 
of anti-TNF therapy > 2 years after diagnosis was inde-
pendently associated with higher risk of ER visit (aHR, 
1.65; 95% CI, 1.13 to 2.41). However, there were no signif-
icant differences in terms of the risk of surgery, hospi-
talization, and corticosteroid use between early (≤ 2 year) 
and late initiators (> 2 years) (Supplementary Table 1). 
DISCUSSION
In this study, using a large population-level claims da-
tabase, we were able to clearly identify an association 
Table 2. Comparison of outcomes between early and late initiators of anti-TNF agent
Variable
Early initiators of anti-TNF
(n = 609)
Late initiators of anti-TNF
(n = 598)
p value
Abdominal surgery outcomes 
Surgery, n (%) 36 (5.9) 51 (8.5) 0.099
Surgery rate, /100 patient-years, 95% CI 2.2 (1.6–3.0) 3.9 (2.9–5.1) 0.008
Time to surgery, yr, median (IQR) 1.03 (0.34–2.05) 1.00 (0.38–2.23) 0.983
ER visit outcomes 
ER visit, n (%) 70 (11.5) 78 (13.0) 0.464
ER visit rate, /100 patient-years, 95% CI 4.2 (3.3–5.3) 5.8 (4.6–7.2) 0.045
Time to ER visit, yr, median (IQR) 1.75 (0.43–2.91) 1.42 (0.67–2.77) 0.721
Hospitalization outcomes
Hospitalization, n (%) 186 (30.5) 155 (25.9) 0.086
Hospitalization rate, /100 patient-years, 95% CI 14.5 (12.5–16.6) 14.2 (12.1–16.5) 0.850
Time to Hospitalization, yr, median (IQR) 0.57 (0.19–1.38) 0.60 (0.19–1.66) 0.761
New steroid use (after 2 months) outcomes
New steroid use, n (%) 82 (13.5) 79 (13.2) 0.964
New steroid use rate, /100 patient-years, 95% CI 5.4 (4.3–6.6) 6.3 (5.0–7.8) 0.292
Time to new steroid use, yr, median (IQR) 1.07 (0.59–1.96) 0.93 (0.49–1.60) 0.480
TNF, tumor necrosis factor; CI, confidence interval; IQR, interquartile range.
1110 www.kjim.org https://doi.org/10.3904/kjim.2020.001
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between early anti-TNF initiation and several beneficial 
clinical outcomes in CD. More specifically, early treat-
ment with anti-TNF agents within 1 year of diagnosis 
was independently associated with reduced risk of ab-
dominal surgery and tended to be associated with re-
duced risk of CD-related ER visit. 
To date, several studies have explored the impact of 
anti-TNF treatment timing on clinical outcomes in 
patients with CD, although the definitions of early an-
ti-TNF initiation and clinical outcomes investigated 
vary slightly among studies. Similar to our results, most 
previous studies have shown more favorable outcomes 
in early initiators than in late initiators. A retrospec-
tive cohort study using the MarketScan Commercial 
and Medicare databases in the United States reported 
a negative association between lagged use of biologics 
and the proportion of patients with IBD-related hospi-
talizations and ER visits [15]. In this study, biologic use 
in the previous year was associated with a 3.8% to 5.6% 
reduction in hospitalizations in the current year, and 
similar results were observed for ER visits [15]. However, 
this study considered patients with both ulcerative coli-
tis (UC) and CD together in a single category despite the 
fact that these two diseases can manifest quite different-
ly. A Spanish study revealed that time between diagnosis 
and anti-TNF initiation was associated with the risk of 
major abdominal surgery in CD [16]. More specifically, 
out of 272 patients who received anti-TNF therapy, 137 
patients who had undergone surgery started anti-TNF 
agents after a median of 166 months (IQR, 90 to 233) after 
diagnosis, while patients who had not undergone sur-
gery started therapy after a median of 59 months (IQR, 
14 to 162; p < 0,005) [16]. The odds ratio for surgery was 
1.008 (95% CI, 1.005 to 1.010) for each month of delay in 
starting anti-TNFs [16]. A Canadian retrospective study 
involving 190 CD patients (100 receiving infliximab and 
90 receiving adalimumab) demonstrated that early ini-
tiation of anti-TNF therapy within the first 2 years of 
diagnosis reduced the rate of surgery and secondary loss 
of response requiring dose escalation [8]. Additionally, 
the Swiss IBD Cohort Study (SIBDCS) involving 540 CD 
patients (the data obtained from patients enrolled in 
SIBDCS between 2006 and 2012) found that treatment 
with anti-TNF agents within the first 2 years of CD di-
agnosis was associated with reduced risk of developing 
bowel strictures, when compared with initiating these 
drugs > 2 years after diagnosis (HR, 0.276; p = 0.018) [9]. 
Recently, the data obtained from SIBDCS involving 
more patients (246 early initiators and 696 late initia-
tors) over a longer period of time (between 2006 and 
2016) also showed that early anti-TNF administration 
within 2 years of CD diagnosis was associated with re-
duced risk of osteoporosis and anemia as well as bowel 
stenosis [10]. Furthermore, patients with early anti-TNF 
administration sought medical consultations signifi-
cantly less frequently (including gastroenterologists in 
private practice, outpatient hospital visits, and a com-
posite of any medical visits) and, by trend, showed lower 
rates of absence from work owing to CD, in contrast to 
patients with late anti-TNF administration [10]. In line 
with these results, a South Korean study reported that 
late anti-TNF/IMs treatment (initiating these drugs > 2 
years after diagnosis) was independently associated with 
higher risks of intestinal surgery (aHR, 2.32), behavior-
al progression (aHR, 2.00), stricturing complications 
(aHR, 1.74), and penetrating complications (aHR, 3.32) in 
patients with CD [11]. However, this study was based on 
the data obtained from a single tertiary referral center 
and included only 79 early anti-TNF initiators and did 
not analyze these patients separately. 
In contrast to the results of our study and previous 
studies, a population-based study in the Netherlands 
did not find a beneficial effect of starting anti-TNF ther-
apy early (< 16 months) in contrast to starting anti-TNF 
therapy late (> 16 months) with respect to surgery, ab-
scess formation, fistula formation, extra-intestinal man-
ifestations (EIMs), and mucosal healing [17]. However, 
the number of patients included in this study was too 
small to draw a definitive conclusion; only 66 CD pa-
tients and 16 UC patients were included, and these two 
diseases were analyzed together. 
The existing literature and our findings support that 
the early use of anti-TNF may alter the natural history 
of CD. Early anti-TNF therapy may rapidly reduce intes-
tinal inflammation before the onset of permanent scar 
formation, thereby inhibiting the development of me-
chanical complications such as fibrostenotic stricturing 
and penetrating disease. The reduction in these irre-
versible complications in the early stages of disease may 
have led to a decrease in the rate of surgeries. However, 
the cost effectiveness of early anti-TNF initiation is a 
matter of concern. Although early initiation of anti-TNF 
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agents can reduce the rates of CD-related complications, 
surgery, or ER visit, these drugs are very expensive. 
Therefore, the longer-term use of anti-TNF agents may 
cause economic burden. Indeed, some studies since the 
advent of biologic agents have reported that increased 
use of anti-TNF agents has been the key driver of CD-re-
lated healthcare costs [18,19]. Recently, a Korean popu-
lation-based study also demonstrated that anti-TNF 
agents accounted for 93.1% of all medication costs and 
68.8% of the total cost in 2015 [20]. However, a Canadi-
an study found that early initiation of anti-TNF therapy 
(both infliximab and adalimumab) within 2 years of CD 
diagnosis provides significant cost savings and quali-
ty-adjusted life-years compared with later initiation [21]. 
This study suggests that early anti-TNF therapy has the 
potential not only to improve clinical outcomes, but also 
to reduce the economic burden associated with CD [21]. 
The cost effectiveness of early initiation of anti-TNF 
therapy may be different between countries, because the 
medical environments vary among different countries 
and the effect of anti-TNF therapy may vary from race to 
race. Thus, more worldwide studies are needed to veri-
fy the cost effectiveness of early initiation of anti-TNF 
therapy. Another concern with early anti-TNF therapy is 
safety, especially in terms of the risk of lymphoma and 
infections. Further large-scale, long-term studies are 
warranted to assess the safety of early anti-TNF therapy.
Interestingly, we found that age at the start of anti-TNF 
was associated with higher risks of surgery, hospitaliza-
tion, and corticosteroid use. In other words, among CD 
patients who received anti-TNF therapy for more than 
6 months, older age at the start of anti-TNF was associ-
ated worse clinical outcomes. This may be because an-
ti-TNF agents are more effective in patients with high 
inflammatory burden and no irreversible changes in 
the intestine. Younger patients usually have more in-
flammatory burden and less irreversible changes in the 
intestine than older patients. Similar to our findings, a 
multi-national, multicenter study revealed that younger 
age at the start of infliximab therapy was associated with 
a beneficial long-term use [22].
To the best of our knowledge, this is the first popula-
tion-based study to assess the impact of early initiation 
of anti-TNF on clinical outcomes of CD patients in Asia. 
However, the present study has some limitations. First, 
disease activity such as clinical, biochemical, or endo-
scopic activity, phenotypes such as the location and be-
havior of CD, and indication of anti-TNF use which can 
affect clinical outcomes, were not considered because 
the administrative data do not include these details. 
However, since infliximab and adalimumab were ap-
proved only for patients with a CD activity index of 220 
or higher in South Korea, the clinical activity of patients 
included in this study may not have been significant-
ly different. Second, although several clinical outcomes 
including surgery were analyzed, more detailed clinical 
outcomes, such as intestinal complications (including 
stenosis, fistula, and abscess), loss of response requiring 
dose escalation of anti-TNF agent, and EIMs, were not 
examined. Third, we were unable to assess the efficacy 
of early anti-TNF therapy for perianal disease because 
the claims codes could not distinguish perianal disease. 
However, we considered the surgical history of perianal 
diseases and this factor was adjusted in our analysis. 
Fourth, the definition of CD-related ER visits may not 
be perfect. ER visits with CD as the primary diagnosis 
may be difficult to accurately regard as CD-related ER 
visits. Lastly, we did not evaluate the cost effectiveness 
and safety of early initiation of anti-TNF therapy. 
Despite these limitations, our study provides a bet-
ter understanding of the impact of the early use of an-
ti-TNF agents on clinical outcomes in patients with CD. 
In conclusion, an association between early anti-TNF 
therapy within 1 year of diagnosis and better clinical 
outcomes, including reduced risks of abdominal sur-
gery and ER visit, was observed in Korean patients with 
CD. Our findings provide evidence supporting that ag-
gressive medical intervention in the early stages of CD 
can potentially change the natural history of the disease 
in relation to surgery and clinical outcomes.
KEY MESSAGE
1. Early treatment with anti-tumor necrosis fac-
tor agents within 1 year of diagnosis was asso-
ciated with reduced risk of abdominal surgery 
and tended to be associated with reduced risk 
of Crohn’s disease (CD)-related emergency 
room visit. 
2. These results suggest that aggressive medical 
intervention in the early stages of CD may po-
tentially change the course of this disease.
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